$10.18
0.88%
Downside
Day's Volatility :3.07%
Upside
2.21%
11.39%
Downside
52 Weeks Volatility :38.09%
Upside
30.13%
Period | Amicus Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.19% | 6.5% | 0.0% |
6 Months | -16.86% | 7.1% | 0.0% |
1 Year | -23.15% | 9.8% | 0.0% |
3 Years | 16.19% | 14.2% | -20.2% |
Market Capitalization | 3.1B |
Book Value | $0.44 |
Earnings Per Share (EPS) | -0.49 |
PEG Ratio | -0.18 |
Wall Street Target Price | 17.4 |
Profit Margin | -34.73% |
Operating Margin TTM | -19.63% |
Return On Assets TTM | -5.08% |
Return On Equity TTM | -126.1% |
Revenue TTM | 423.5M |
Revenue Per Share TTM | 1.42 |
Quarterly Revenue Growth YOY | 28.000000000000004% |
Gross Profit TTM | 290.6M |
EBITDA | -49.0M |
Diluted Eps TTM | -0.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.22 |
EPS Estimate Next Year | 0.23 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.02 |
What analysts predicted
Upside of 70.92%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 91.2M | ↑ 147.08% |
Net Income | -349.0M | ↑ 22.88% |
Net Profit Margin | -382.48% | ↑ 386.55% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 182.2M | ↑ 99.72% |
Net Income | -356.4M | ↑ 2.12% |
Net Profit Margin | -195.56% | ↑ 186.92% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 260.9M | ↑ 43.16% |
Net Income | -276.9M | ↓ 22.32% |
Net Profit Margin | -106.12% | ↑ 89.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 305.5M | ↑ 17.11% |
Net Income | -250.5M | ↓ 9.53% |
Net Profit Margin | -81.98% | ↑ 24.14% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 329.2M | ↑ 7.76% |
Net Income | -236.6M | ↓ 5.55% |
Net Profit Margin | -71.85% | ↑ 10.13% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 399.4M | ↑ 21.3% |
Net Income | -151.6M | ↓ 35.92% |
Net Profit Margin | -37.96% | ↑ 33.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 88.1M | ↑ 7.84% |
Net Income | -55.9M | ↑ 67.83% |
Net Profit Margin | -63.41% | ↓ 22.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 86.3M | ↓ 2.07% |
Net Income | -52.9M | ↓ 5.25% |
Net Profit Margin | -61.36% | ↑ 2.05% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 94.5M | ↑ 9.54% |
Net Income | -43.2M | ↓ 18.33% |
Net Profit Margin | -45.75% | ↑ 15.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 103.5M | ↑ 9.52% |
Net Income | -21.6M | ↓ 50.09% |
Net Profit Margin | -20.85% | ↑ 24.9% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 115.1M | ↑ 11.19% |
Net Income | -33.8M | ↑ 56.85% |
Net Profit Margin | -29.41% | ↓ 8.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 110.4M | ↓ 4.07% |
Net Income | -48.4M | ↑ 43.07% |
Net Profit Margin | -43.86% | ↓ 14.45% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 790.0M | ↑ 25.98% |
Total Liabilities | 447.0M | ↑ 63.05% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 850.2M | ↑ 7.63% |
Total Liabilities | 373.8M | ↓ 16.39% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 886.5M | ↑ 4.27% |
Total Liabilities | 600.1M | ↑ 60.56% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 905.1M | ↑ 2.1% |
Total Liabilities | 597.8M | ↓ 0.39% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 724.2M | ↓ 19.99% |
Total Liabilities | 601.1M | ↑ 0.56% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 777.9M | ↑ 7.42% |
Total Liabilities | 617.7M | ↑ 2.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 724.2M | ↓ 4.66% |
Total Liabilities | 601.1M | ↓ 4.12% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 700.5M | ↓ 3.27% |
Total Liabilities | 597.9M | ↓ 0.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 730.1M | ↑ 4.22% |
Total Liabilities | 618.5M | ↑ 3.44% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 764.1M | ↑ 4.66% |
Total Liabilities | 630.8M | ↑ 1.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 777.9M | ↑ 1.81% |
Total Liabilities | 617.7M | ↓ 2.08% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 721.8M | ↓ 7.21% |
Total Liabilities | 591.1M | ↓ 4.31% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -300.0M | ↑ 39.2% |
Investing Cash Flow | -121.2M | ↓ 29.22% |
Financing Cash Flow | 450.8M | ↑ 82.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -250.4M | ↓ 16.52% |
Investing Cash Flow | 95.2M | ↓ 178.51% |
Financing Cash Flow | 217.5M | ↓ 51.75% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -233.3M | ↓ 6.84% |
Investing Cash Flow | -13.6M | ↓ 114.27% |
Financing Cash Flow | 262.9M | ↑ 20.85% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -202.5M | ↓ 13.2% |
Investing Cash Flow | 78.8M | ↓ 680.02% |
Financing Cash Flow | 212.1M | ↓ 19.32% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -166.6M | ↓ 17.74% |
Investing Cash Flow | 92.3M | ↑ 17.21% |
Financing Cash Flow | -7.5M | ↓ 103.52% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -80.8M | ↑ 594.75% |
Investing Cash Flow | -66.7M | ↓ 189.52% |
Financing Cash Flow | 557.0K | ↓ 199.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.1M | ↓ 77.63% |
Investing Cash Flow | 36.3M | ↓ 154.35% |
Financing Cash Flow | -7.8M | ↓ 1504.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↓ 10.71% |
Investing Cash Flow | 50.0M | ↑ 37.91% |
Financing Cash Flow | 23.7M | ↓ 402.53% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.3M | ↑ 137.69% |
Investing Cash Flow | 35.8M | ↓ 28.47% |
Financing Cash Flow | 37.6M | ↑ 58.91% |
Sell
Neutral
Buy
Amicus Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Amicus Therapeutics, Inc. | 5.77% | -16.86% | -23.15% | 16.19% | -19.34% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Amicus Therapeutics, Inc. | NA | NA | -0.18 | -0.22 | -1.26 | -0.05 | NA | 0.44 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Amicus Therapeutics, Inc. | Buy | $3.1B | -19.34% | NA | -34.73% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Amicus Therapeutics, Inc.
Revenue is down for the last 2 quarters, 115.08M → 110.40M (in $), with an average decrease of 4.1% per quarter
Netprofit is down for the last 3 quarters, -21.57M → -48.41M (in $), with an average decrease of 50.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 84.7%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 170.3%
Vanguard Group Inc
Perceptive Advisors LLC
venBio Select Advisor LLC
BlackRock Inc
Wellington Management Company LLP
JPMorgan Chase & Co
Amicus Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Moreamicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Organization | Amicus Therapeutics, Inc. |
Employees | 517 |
CEO | Mr. Bradley L. Campbell M.B.A. |
Industry | Health Technology |
Outfront Media Inc.
$10.18
-0.78%
Blackrock Short Duration Bond Etf
$10.18
-0.78%
Moog Inc
$10.18
-0.78%
Edgio Inc.
$10.18
-0.78%
Invesco S&p 500 Momentum Etf
$10.18
-0.78%
Silicon Laboratories Inc
$10.18
-0.78%
Helmerich & Payne, Inc.
$10.18
-0.78%
Crane Nxt Co
$10.18
-0.78%
Liberty Global Plc - Class C Shares
$10.18
-0.78%